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INTRODUCTION
Resistance to thyroid hormone (RTH) is a syndrome involving
reduced responsiveness of target tissues to thyroid hormone (TH)
(1). Patients with all RTH all have non-suppressed thyroid-stimu-
lating hormone (TSH) levels despite elevated free thyroxine (FT4)
and free triiodothyronine (FT3) levels, unless they have a co-ex-
isting thyroid disease such as Graves’ disease or thyroid autonomy.
This condition is known as the syndrome of inappropriate secre-
tion of TSH (SITSH) (2). Patients with TSH-secreting pituitary
tumors (TSHoma) and RTH often exhibit SITSH. In majority of pa-
tients with RTH, this condition is caused by mutations in the thy-
roid hormone receptor (TR) β gene (3).
This rare case is an important addition to the literature because
there have been few reports on hormone replacement therapy in
a patient with RTH and thyroid cancer after total thyroidectomy.
CASE PRESENTATION
A 54-year-old woman was admitted to our hospital because a
chest X-ray showed abnormal calcification in the bilateral lobes of
the thyroid. She had no typical thyrotoxic signs or symptoms and
there was no relevant family history of thyroid disease.
On palpation, her thyroid was mildly enlarged. Electrocardiog-
raphy showed regular sinus rhythm. On the initial laboratory ex-
amination before the operation, thyroid function tests demonstrated
slightly elevated values of FT3 and FT4, and TSH was within the
normal range. (FT3 6.3 [range, 2.3 -4.1] pg/mL, FT4 3.0 [0.7 -1.7]
ng/dL, TSH 4.03 [0.5 -4.3] μU/mL). Anti - thyroglobulin antibody
and anti - thyroid peroxidase antibody were negative, suggesting no
chronic thyroiditis. Thyroglobulin was elevated (90 [0-32.7] ng/
mL), thyroid-stimulating antibody and TSH-binding inhibitor im-
munoglobulin levels were not measured (Table 1).
Ultrasonography showed some masses in the bilateral lobes
(one nodule in the right lobe and three nodules in the left lobe).
They were hypoechoic and calcified masses, approximately 1 cm
in size.
Fine needle aspiration was performed for the nodule with fea-
tures suggestive of malignancy in the left lobe (Figure 1), and the
cytologic diagnosis was papillary carcinoma.
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Table 1. Blood chemistry results
Normal range
WBC 6.7 103/μl 4.0 -9.5
RBC 4.92 106/μl 3.5 -5.0
Hemoglobin 14.8 g/dl 11.0 -15.0
Hematocrit 42.4 ％ 35.0 -45.1
Platelets 20.9 104/μl 130 -400
Ca 9.7 mg/dl 8.0 -11.0
P 3.6 mg/dl 2.5 -4.5
FT3 6.3 pg/ml 2.3 -4.1
FT4 3 ng/dl 0.7 -1.7
TSH 4.03 μU/ml 0.5 -4.3
Anti -Tg Ab 10 mg/l 0 -40.6
Anti -TPO Ab 1.7 mg/l 0 -5.2
Tg 90 ng/ml 0-32.7
WBC : white blood cells, RBC : red blood cells, FT3 : free triiodothy-
ronine, FT4 : free thyroxine, TSH : thyroid-stimulating hormone, anti -
Tg Ab : anti-thyroglobulin antibody, anti -TPO Ab : anti - thyroid peroxi-
dase antibody, Tg : thyroglobulin
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The patient underwent total thyroidectomy and cervical lymph
node dissection. Final postoperative pathology revealed four tu-
mors of papillary carcinoma (10 mm7 mm in the right lobe and
4 mm4 mm, 10 mm8 mm, and 4 mm3 mm in the left lobe),
with no metastases to the cervical lymph nodes. On postoperative
day 7, she received L-T4 therapy at 100 μg/day. After 1 month of
L-T4 therapy, her TSH levels were markedly elevated (FT3 2.9
pg/mL, FT4 1.5 ng/dL, and TSH 103.7 μU/mL). Two months after
surgery, the TSH levels were still elevated (FT3 2.7 pg/mL, FT4
1.6 ng/dL, and TSH 102.09 μU/mL). Therefore, the dose of L-T4
was increased from 100 μg to 125 μg daily. Three months post-
surgery, the TSH levels were lower (FT3 3.4 pg/mL, FT4 1.8 ng/
dL, and TSH 87.45 μU/mL), and the dose of L-T4 was decreased
to 100 μg/day. However, 4 months later, the TSH level was ele-
vated again (FT3 2.6 pg/mL, FT4 1.5 ng/dL, and TSH 108.56 μU/
mL). The dose of L-T4 was again increased to 125 μg/day, but the
TSH levels were not suppressed despite the elevated FT4 (FT3
3.2 pg/mL, FT4 2.1 ng/dL, and TSH 112.59 μU/mL). TSHoma or
RTH was then suspected, thus magnetic resonance imaging (MRI)
of the brain was performed, but no tumors were found in the pi-
tuitary gland (Figure 2), suggesting RTH. Written permission was
received from the patient for gene analysis of TRβ as approved by
the committee of Tokushima Municipal Hospital. Genomic DNA
was isolated from the peripheral blood, and the DNA sequence
analysis of the TRβ gene revealed a heterozygous point mutation,
CCT to TCT, resulting in substitution of proline by serine at codon
453 (P453S), which has been found previously (Figure 3). Ulti-
mately, she was diagnosed with RTH 7 months after surgery. Gene
analysis was recommended to her family, but they declined.
The dose of L-T4 was increased to 350 μg/day. The latest thy-
roid function tests showed that the TSH level was still slightly sup-
pressed (FT3 6.0 pg/mL, FT4 4.5 ng/dL, and TSH 0.45 μU/mL),
and she had no thyrotoxic symptoms (Figure 4). There has been no
recurrence or metastasis of thyroid cancer 27 months post surgery.
DISCUSSION
RTH is a syndrome that involves reduced tissue sensitivity to TH
(1). Patients with RTH have non-suppressed TSH levels despite ele-
vated FT4 and FT3 levels, unless they have a co-existing thyroid
disease such as Graves’ disease or thyroid autonomy, this condi-
tion is known as SITSH (2). Approximately 85% of RTH kindred
cases are caused by mutations in the TRβ gene, which is passes
on by autosomal dominant inheritance (3). However, RTH cannot
necessarily be ruled out just because there are no mutations in
the TRβ gene (4).
Figure 1. Ultrasonography of the thyroid.
Thyroid ultrasonography showed some masses in the bilateral lobes
(one nodule in the right lobe and three nodules in the left lobe) suggest-
ing malignancy. Fine needle aspiration was performed for the nodule
with features suggestive of a malignancy in the left lobe (arrow).
Figure 2. MRI of the brain.
No tumors were found in the pituitary gland.
Figure 3. Sequence analysis of the TRβ gene.
Sequence analysis of the TRβ gene revealed a heterozygous point mu-
tation, CCT to TCT, resulting in substitution of proline by serine at co-
don 453 (P453S).
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In most patients with RTH, TSH is inappropriately secreted and
stimulates the thyroid gland continuously. Thus, such patients’ thy-
roid glands appear mildly enlarged, and iodine123 scintigraphy shows
diffuse enlargement of the thyroid gland with increased uptake.
Some patients with RTH have thyrotoxic signs and symptoms, such
as tachycardia, atrial fibrillation, attention deficit disorder, and hy-
peractivity (4-7). On laboratory examination, thyroid function tests
show unsuppressed TSH levels despite elevated FT4 and FT3 levels
(2). In particular, FT4 is elevated in most cases (4, 5).
If thyroid function tests suggest SITSH, assay interference should
be excluded, it is occasionally necessary to change the measure-
ment method. If laboratory dates still suggest SITSH, then RTH or
TSHoma are suspected, and the patient’s family history should
first be confirmed. If the patient has no family history of RTH, the
next step is to check for a pituitary tumor using MRI to rule out
the possibility of TSHoma. In patients with a family history of RTH
or those with no lesions in the pituitary gland, analysis of the TRβ
gene should be performed to confirm a diagnosis of RTH. A diag-
nosis of RTH can be made if there is a mutation of the TRβ gene.
In the present case, the patient’s thyroid function tests on initial
laboratory examination showed slightly elevated values of FT3 and
FT4, with TSH in the normal range. RTH was not suspected at that
point, because there was no significant family history or symptoms
of hyperthyroidism or hypothyroidism. However, her thyroid func-
tion should have been assessed again before the operation. Al-
though the treatment policy was not changed as a result, she may
have been able to receive suitable hormone replacement therapy
soon after surgery.
Treatment of RTH is unnecessary if the patient has no symptoms.
In patients with hypothyroidism, a trial of TH therapy can be consid-
ered. If hyperthyroidism is present, β adrenergic blocking agents
and other appropriate agents should be given (4, 6). In the present
case, the patient underwent total thyroidectomy for thyroid cancer,
and thus required hormone replacement therapy. Two experts
(Yoshitaka Hayashi, Associate Professor, and Yoshiharu Murata,
former Professor of the Research Institute of Environmental Medi-
cine of Nagoya University) were consulted on how to control the
dose of L-T4 in the present case, and they suggested that the pa-
tient should have received the appropriate L-T4 dose to achieve
the preoperative TSH level. A few cases of RTH with total thyroi-
dectomy have been reported (8, 9), and the TH levels as were con-
trolled in the present case. Moreover, another case report sug-
gested that the family’s mean THS level should be used as the
target for L-T4 replacement therapy (10). However, this is not
available in sporadic RTH patients. Furthermore, the authors of
the above study did not evaluate the effect of L-T4 therapy after
the operation on the patient’s long-term circulatory and physiologi-
cal status, as well as the prognosis and treatment results of thyroid
cancer in such cases.
The method used in the present case appears to be physiologic
and suitable as an improved approach to the patient’s preoperative
condition, although there is no clear evidence to support this. Ad-
ditionally, I think that estimation of other clinical data, for exam-
ple, change in body weight, heart rate, creatine kinase, and alka-
line phosphatase, would have been useful for evaluating TH level
in the patient.
In the present case, it was necessary to increase the dose of L-
T4 to suppress the TSH levels to the normal range or less and to
prevent stimulating malignant cells based on the general guidelines
for thyroid cancer. The patient currently receives 350 μg/day L-T4
and has no thyrotoxic symptoms. There has been no recurrence
or metastasis of thyroid cancer 27 months after the surgery.
Figure 4. Clinical course of the patient.
L -T4 : levothyroxine
The figure shows the thyroid function tests and the dose of L-T4 after the surgery.
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In patients with RTH, TSH is unsuppressed. Therefore, the nec-
essary dose of L-T4 will increase if the patient needs hormone re-
placement therapy, which could cause thyrotoxic symptoms in such
patient (4, 5). In addition, there have been a few reports on the
long term treatment results of thyroid cancer in such cases. In the
present case, the patient will be observed, and the effect of L-T4
therapy will be followed up. Although long- term observation is not
possible, I have considered and addressed these issues, and I think
that this report provides useful information.
Moreover, my patient had papillary carcinoma. Approximately
95% of RTH patients have diffuse goiter, and continuous stimula-
tion of the thyroid by excess TSH may be related to the formation
of thyroid nodules and growth of thyroid cancer (8). However, the
contribution of RTH to thyroid tumorigenesis is not fully under-
stood, and there is no confirmatory evidence. Further studies on
the association between thyroid cancer and RTH are warranted
and I must carefully observe and evaluate my patient for recur-
rence and metastasis.
CONCLUSIONS
In conclusion, a patient diagnosed with RTH after total thyroidec-
tomy for thyroid cancer was described. It is difficult to decide on
the most appropriate dose of TH in these situations and further
investigation is required.
LIST OF ABBREVIATIONS
RTH : resistance to thyroid hormone
TSH : thyroid-stimulating hormone
SITSH : syndrome of inappropriate secretion of TSH
FT3 : free triiodothyronine
FT4 : free thyroxine
L-T4 : levothyroxine
MRI : magnetic resonance imaging
TR : thyroid hormone receptor
TH : thyroid hormone
TSHoma : TSH-secreting pituitary tumors
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